Swiss multinational healthcare company
F. Hoffmann-La Roche AG is one of the two Basel-anchored pharmaceutical giants that together define Switzerland's life-sciences cluster. Founded in 1896 by Fritz Hoffmann-La Roche, the company generated roughly CHF 60 billion in 2024 revenue across its Pharmaceuticals division (Genentech, Chugai, and in-house Basel operations) and its Diagnostics division (global leader in in-vitro diagnostics).
Roche employs around 103,000 people globally and is a top-three pharma company by market capitalization.
The listed entity Roche Holding AG trades on SIX Swiss Exchange under ticker ROG and files sponsored ADRs traded OTC in the US under RHHBY. Roche's share structure is unusual: founding-family-linked heirs (the Hoffmann and Oeri families plus related interests) control the voting bearer shares, while public investors mostly hold non-voting participation certificates (Genussscheine).
That dual-class structure has kept Roche immune to activist pressure and takeover attempts for decades and is one of the last major European examples of family-anchored pharma governance.
Operationally, Roche is Basel-based. The listed AG, the research labs, and group treasury all sit in Canton Basel-Stadt, the traditional Swiss pharmaceutical canton alongside Basel-Landschaft.
Roche is the canonical example of how a Swiss Aktiengesellschaft can protect family control across generations while accessing global capital markets. Most listed companies in the US and UK are now prohibited from issuing dual-class shares at IPO or must sunset them within a decade. Swiss corporate law does not impose that constraint.
Roche's founding families have maintained voting control since 1896 by keeping bearer shares (stimmrechtsaktien) in a family pool while issuing non-voting participation certificates to the public.
This matters for Swiss structuring because it proves that cantonal law tolerates protective share classes even at megacap scale. Canton Basel-Stadt registers the Roche AG, which means the dual-class structure is explicitly sanctioned by a Swiss cantonal commercial registrar.
Founders replicating this should note that the participation certificate (Genussschein) is a Swiss-specific instrument - it is not quite preferred stock in the US sense, it is not quite tracking stock, and it does not exist in UK, German, or French company law in the same form. US and UK investors often require education before accepting it.
The second lesson is the Swiss-plus-ADR pattern. Roche lists its bearer shares on SIX and separately sponsors an OTC ADR program for US institutional access. This is the middle path between Nestle (Swiss-only, unsponsored ADRs) and Novartis (sponsored NYSE dual listing). The OTC route is cheaper to maintain, does not require SEC 20-F filings, and still gives US mutual funds clean access.
For a mid-sized Swiss AG planning international capital raises, OTC-sponsored ADRs are usually the right first step before graduating to NYSE or NASDAQ.
Third, Roche demonstrates the economic depth of Basel-Stadt as a canton. The cantonal corporate income tax rate runs around 13%, which combined with federal tax lands at roughly 13-14% all-in - competitive with Zug and below Zurich or Geneva. Basel-Stadt also provides dense life-sciences talent, proximity to European regulators, and specialised Zefix registrar experience with pharma-specific filings.
Novartis chose the same canton for the same reasons.
Yes. The Hoffmann and Oeri family branches, together with their related family pool, hold a controlling block of voting bearer shares. Public investors mostly hold non-voting participation certificates (Genussscheine).
A participation certificate under Swiss corporate law. It gives economic rights (dividends, liquidation proceeds) but no voting rights. It is a Swiss-specific instrument and does not map cleanly to preferred stock or tracking stock in US or UK law.
Both are headquartered in Canton Basel-Stadt and face essentially identical cantonal and federal corporate income tax rates, around 13-14% all-in. The meaningful tax differences sit in their respective international transfer-pricing structures.
Roche trades via sponsored ADRs on the OTC market under ticker RHHBY. Unlike Novartis (NYSE: NVS), Roche does not maintain a primary US listing. The OTC route is cheaper and avoids SEC 20-F filing.
